In June 2022, Happify Health and Almirall announced the launch of Claro, a digital platform built to improve mental health for those living in Spain, the United Kingdom, or Italy with psoriasis. Claro focuses on cognitive behavioral therapy, positive psychology, and mindfulness and is the first iteration of Happify Health’s platform for people living with psoriasis. Claro is available in English, Spanish, Italian, and French.
What happened in psoriasis at the 2026 EADV Congress? IPC shares highlights from its symposium on personalized medicine, as well as psoriasis sessions and late-breaking research from Vienna.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
Can a psoriasis patient with cancer still receive biologic therapy? IPC’s newest manuscript gives dermatologists and oncologists a shared, evidence-based answer, including which therapies to favor, which to avoid, and why the two specialties need to decide together.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
